Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Palbociclib

Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).

DRUG

Dexamethasone

20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).

DRUG

Lenalidomide

Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).

Trial Locations (1)

10065

Weill Cornell Medical College, New York

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER